← Back

Natera: Natera's Q4 2025 Earnings: Strong Revenue Growth and Margin Expansion

Natera's Q4 2025 financial results were impressive, with revenue reaching $666 million, a 40% increase from Q4 2024, and $6 million ahead of the preannouncement. The company's gross margin was 66.9%, with a record organic gross margin quarter at 63.7%. The earnings per share (EPS) came out at $0.35, significantly better than the estimated -$0.51207. The strong financial performance was driven by a record 924,000 tests processed, with MRD clinical units growing 56% year-over-year to 225,000 tests.

NTRA

USD 208.04

-3.73%

A-Score: 4.7/10

Publication date: February 26, 2026

Full Report

Author: Analystock.ai

📋 Highlights
  • Revenue & Margin Growth: Q4 revenue reached $666 million (40% YoY), with a record organic gross margin of 63.7% and overall gross margin of 66.9%.
  • MRD Expansion: MRD clinical units surged 56% YoY to 225,000 tests, driven by genome Signatera and Latitude launches, with exome volume as the majority.
  • 2026 Guidance: Revenue projected at $2.62–$2.7 billion (25% growth), with gross margins targeting 63–65%, up from 61.5% in 2025.
  • Cash Flow & Balance Sheet: Generated $107 million cash flow in 2025 and held $1 billion in cash/securities, achieving Q4 net income.
  • R&D & Product Launches: Phase Variant technology improved ctDNA detection to 1 part per 10 million, and Latitude submitted to MolDx for colorectal cancer, expanding MRD moat.

Revenue Growth and Margin Expansion

The company's revenue growth was driven by continued expansion in its women's health and organ health products. The gross margin improvement was a result of operational leverage and efficiency gains. Natera's guidance for 2026 expects revenues between $2.62 billion and $2.7 billion, with gross margins between 63% and 65%. The company expects to continue to improve margins in 2026, driven by its focus on operational efficiency and volume growth.

Product Launches and Clinical Studies

Natera made significant investments in product launches and clinical studies in 2025. The company expanded its MRD product portfolio with the launch of the genome version of Signatera and the Latitude MRD test. The Fetal Focus test has shown robust performance, with 96% sensitivity and 98% specificity. The company also presented data on its Prospera donor DNA monitoring in organ health and its Signatera test in oncology, including exceptional momentum in bladder cancer.

Valuation Metrics

Natera's current valuation metrics indicate a high-growth profile. The company's Price-to-Sales Ratio is 12.58, and the EV/EBITDA ratio is -109.1. The Return on Invested Capital (ROIC) is -11.81%, indicating that the company's investments are not yet generating positive returns. However, the company's strong revenue growth and margin expansion are expected to drive future returns.

Growth Prospects

Natera guides for 25% revenue growth in 2026, driven by continued growth in women's health volumes and ASPs, and another strong year of growth for organ health products, including Signatera. The company expects Signatera to continue growing sequentially quarter-over-quarter, with a strong start to 2026. The analysts' estimates for next year's revenue growth are 19.8%, indicating a high-growth profile for the company.

Natera's A-Score